BMX and cancer: A detailed analysis revealed consistent downregulation of BMX expression across various patients' clinical parameters, including age, gender, race, and clinical stage, in the five cancer types compared to the normal tissues; notably, stage III was significantly varied from stage II, and stage IV in BRCA, and LUSC with stage III significantly varied from stage I and stage II which agreed with the analysis performed by GEPIA.